vaccin
inactiv
attenu
subunit
peptid
vector
diva
nucleic
acid
tradit
vaccin
technolog
base
killedinactiv
liveattenu
approach
novel
killedinactiv
vaccin
strategi
includ
antigen
subunit
protein
peptid
vaccin
novel
liveattenu
vaccin
strategi
includ
modifi
live
markerdifferenti
infect
vaccin
anim
vector
nucleic
acid
vaccin
new
vaccin
technolog
often
find
first
commerci
applic
within
veterinari
medicin
vaccin
avail
today
reli
either
inactiv
kill
live
attenu
weaken
technolog
approach
success
use
address
mani
import
veterinari
human
diseas
howev
techniqu
limit
associ
potenti
problem
inactiv
vaccin
must
total
innocu
noninfect
problem
field
outbreak
past
occasion
attribut
incomplet
inactiv
problem
would
exist
reliabl
inactiv
inactiv
procedur
innocu
test
use
within
manufactur
process
furthermor
manufactur
vaccin
involv
cultur
larg
amount
infecti
agent
potenti
hazard
personnel
involv
environ
vaccin
grown
egg
tissu
cultur
simpli
cultur
medium
may
contain
unwant
foreign
protein
could
affect
immunogen
potenti
allergenicreactogen
final
inactiv
vaccin
certain
limit
mode
present
consequ
natur
immun
respons
elicit
respons
vaccin
may
limit
short
durat
adjuv
immunostimul
requir
enhanc
overal
immunogenicityefficaci
attenu
vaccin
must
precis
control
character
order
provid
requir
level
protect
immun
without
caus
signific
diseas
symptom
within
host
anim
also
low
risk
attenu
antigen
may
revert
full
virul
care
revers
virul
safeti
studi
must
carri
furthermor
cultur
vaccin
antigen
possibl
infecti
agent
may
introduc
could
lead
undesir
side
effect
vaccin
use
field
reason
includ
protect
efficaci
economi
manufactur
whether
infecti
agent
produc
vitro
scientist
turn
attent
new
vaccin
technolog
vaccin
technolog
includ
splitproduct
subunit
isol
protein
peptid
marker
vaccin
live
vector
nucleic
acid
approach
identifi
suitabl
subunit
protein
peptid
antigen
vaccin
candid
natur
splitproduct
subunit
vaccin
must
deliv
target
anim
order
elicit
desir
protect
immun
respons
simplest
basic
form
subunit
vaccin
one
infecti
agent
simpli
disassembl
broken
compon
part
current
influenza
vaccin
known
splitproduct
vaccin
consist
formalin
inactiv
viru
treat
order
lyse
viral
envelop
releas
extern
envelop
protein
intern
nuclear
matrix
protein
refin
use
purifi
envelop
glycoprotein
hemagglutinin
neuraminidas
alon
subunit
vaccin
order
reduc
risk
toxic
side
effect
unfortun
splitproduct
subunit
vaccin
influenza
tend
reduc
immunogen
compar
whole
viru
product
attempt
improv
situat
concentr
modifi
antigen
present
deliv
viral
glycoprotein
within
lipid
vesicl
compos
either
virusderiv
lipid
virosom
ad
nonvir
lipid
liposom
way
artifici
empti
virus
creat
display
improv
immunogen
polymer
prepar
isol
protein
form
micel
also
immunogen
protein
monom
recent
time
multimer
present
system
often
collect
refer
viruslik
particl
vlp
develop
offer
polymer
present
builtin
adjuv
activ
enhanc
immunogen
immunostimul
complex
iscom
first
success
commerci
veterinari
applic
technolog
equin
influenza
vaccin
studi
mucos
deliveri
split
product
cell
cultur
subunit
vaccin
also
current
market
felin
leukemia
viru
felv
diseas
although
shown
immunogen
overal
degre
efficaci
particularli
face
oronas
challeng
inconsist
howev
present
surfac
glycoprotein
felv
iscom
neutral
antibodi
elicit
vaccin
cat
complet
protect
demonstr
subsequ
oronas
challeng
well
new
gener
veterinari
viral
subunit
vaccin
mani
current
bacteri
vaccin
base
toxin
pilu
subunit
although
antitoxin
antibodi
neutral
harm
effect
bacteri
infect
antipilu
antibodi
block
colon
prevent
attach
good
exampl
franci
fimbrial
adhes
antigen
enterotoxigen
escherichia
coli
etec
current
vaccin
use
prevent
neonat
diarrhea
calv
pig
inde
e
coli
strain
engin
overproduc
antigen
probabl
first
exampl
use
recombin
dna
technolog
develop
improv
commerci
vaccin
vaccin
produc
use
overexpress
protein
recov
genet
modifi
e
coli
provid
link
natur
subunit
vaccin
deriv
use
recombin
dna
technolog
although
subunit
vaccin
produc
natur
infecti
agent
still
fulfil
import
role
cost
produc
purifi
immunogen
prohibit
inde
immunogen
protein
identifi
becom
goal
mani
research
produc
larg
quantiti
protein
suffici
pure
form
gener
safe
effect
vaccin
emerg
recombin
dna
technolog
meant
foreign
gene
could
insert
express
vector
introduc
cell
act
product
factori
foreign
protein
encod
gene
mani
case
provid
rel
inexhaust
cheap
sourc
protein
infecti
agent
vaccin
studi
bacteri
express
first
recombin
express
system
establish
use
e
coli
bacteria
natur
choic
use
develop
earli
concept
understand
molecular
biolog
express
system
provid
rel
larg
quantiti
defin
protein
thu
herald
answer
mani
subunit
vaccin
howev
fact
prokaryot
cell
differ
mechan
process
traffick
express
protein
often
incorrectli
fold
addit
signal
sequenc
glycosyl
site
disulfid
bond
occur
mani
candid
vaccin
protein
either
result
toxic
insolubl
rapid
degrad
within
bacterium
nevertheless
one
first
recombin
veterinari
vaccin
success
produc
base
surfac
glycoprotein
felv
express
e
coli
known
protein
yeast
express
widespread
use
saccharomyc
cerevisia
baker
yeast
industri
microorgan
made
natur
choic
altern
antigen
protein
express
system
ad
advantag
prokaryot
system
posttransl
modif
protein
carri
manner
similar
use
higher
eukaryot
cell
therefor
recombin
protein
like
correctli
fold
yeastexpress
protein
also
glycosyl
although
glycosyl
distinct
carri
mammalian
cell
develop
yeast
express
concentr
explor
potenti
anoth
strain
yeast
pichia
pastori
use
express
human
hepat
b
vaccin
base
viru
surfac
antigen
hbsag
level
high
mgl
express
level
higher
report
level
protein
cerevisia
insect
cell
express
recent
highli
novel
express
system
develop
use
insect
ovarian
cell
spodoptera
frugiperda
infect
baculoviru
vector
autographa
californica
nuclear
polyhedrosi
viru
virus
possess
strong
promot
control
product
polyhedron
protein
accumul
eventu
constitut
total
infect
cell
protein
therefor
replac
polyhedrin
gene
select
foreign
gene
high
level
recombin
protein
may
produc
protein
also
undergo
posttransl
modif
includ
glycosyl
phosphoryl
signal
peptid
cleavag
howev
glycosyl
pattern
known
differ
seen
mammalian
cellderiv
protein
express
level
high
g
per
liter
could
expect
although
actual
level
vari
consider
mg
depend
antigen
insect
cell
express
success
use
veterinari
vaccin
porcin
circoviru
type
classic
swine
fever
csf
mammalian
cell
express
mani
veterinari
pathogen
infect
replic
cultur
mammalian
cell
would
appear
natur
choic
express
system
one
desir
authent
process
protein
subunit
vaccin
howev
present
sever
technic
problem
express
level
somewhat
lower
achiev
use
altern
express
system
describ
nevertheless
sever
system
avail
express
protein
mammalian
cell
success
use
express
candid
vaccin
protein
bovin
viral
diarrhea
bvd
csf
vlp
japanes
enceph
viru
identifi
sequenc
import
immunogen
site
infecti
agent
mani
case
mimick
use
short
chain
amino
acid
peptid
first
indic
peptid
vaccin
potenti
demonstr
use
plant
viru
tobacco
mosaic
viru
studi
chemic
isol
hexapeptid
fragment
viru
coat
protein
coupl
bovin
serum
albumin
use
elicit
rabbit
antibodi
would
neutral
infecti
viru
two
year
later
synthet
form
peptid
use
confirm
observ
howev
year
next
exampl
peptid
elicit
antiviru
antibodi
appear
follow
work
sela
colleagu
viru
infect
bacteria
bacteriophag
emerg
access
techniqu
sequenc
protein
coupl
abil
readili
synthes
peptid
develop
merrifield
led
upsurg
experiment
peptid
vaccin
research
first
demonstr
peptid
could
elicit
protect
immun
vivo
addit
neutral
activ
vitro
obtain
use
anim
viru
footandmouth
diseas
viru
fmdv
detail
studi
enzym
chemic
cleav
fragment
viral
protein
viru
fmdv
serotyp
identifi
region
amino
acid
found
surfac
viru
fragment
contain
region
abl
induc
neutral
antibodi
homolog
viru
studi
use
chemic
synthes
peptid
correspond
sever
region
led
identif
similar
site
molecul
coupl
protein
carrier
keyhol
limpet
hemocyanin
klh
inocul
franci
guinea
pig
would
rais
neutral
antibodi
could
protect
experiment
infect
although
earli
studi
peptid
immunogen
activ
less
seen
inactiv
viru
particl
equal
weight
basi
level
neutral
antibodi
produc
sever
order
magnitud
greater
obtain
whole
molecul
observ
laboratori
anim
model
subsequ
support
demonstr
protect
immun
peptid
vaccin
cattl
pig
candid
peptid
identifi
predict
must
deliv
immun
system
suitabl
manner
order
elicit
high
titer
antipeptid
respons
also
antipeptid
antibodi
recogn
neutral
infecti
agent
inde
wide
held
view
due
rel
small
molecular
size
peptid
poor
immunogen
thu
requir
carriercoupl
enhanc
immunogen
mani
exampl
elegantli
defin
peptid
coupl
uncontrol
manner
larg
undefin
carrier
protein
produc
antipeptid
antibodi
total
fail
recogn
nativ
protein
defin
peptid
coupl
uncontrol
manner
larg
undefin
carrier
protein
produc
antipeptid
antibodi
total
fail
recogn
nativ
protein
concept
peptid
behav
like
hapten
mani
case
misguid
experi
use
peptid
fmdv
demonstr
role
klh
carrier
prime
peptid
respons
fundament
differ
role
hapten
prime
uncoupl
peptid
peptid
coupl
differ
carrier
tetanu
toxoid
could
boost
respons
peptideklh
prime
anim
observ
led
demonstr
helper
tcell
bcell
determin
rel
small
peptid
inde
clear
uncoupl
peptid
immunogen
provid
contain
appropri
antibodi
recognit
site
bcell
epitop
well
site
capabl
elicit
tcell
help
antibodi
product
thcell
epitop
thcell
epitop
must
interact
class
ii
major
histocompat
complex
mhc
molecul
surfac
antigenpres
cell
b
cell
subsequ
bind
tcell
receptor
form
trimolecular
complex
th
cell
provid
signal
form
chemic
messeng
lymphokin
specif
b
cell
result
differenti
prolifer
antibodi
product
knowledg
synthet
peptid
construct
appropri
site
antibodi
product
plu
addit
tcell
epitop
approach
exploit
use
peptid
contain
bcell
epitop
within
consensu
sequenc
base
residu
asian
type
virus
link
promiscu
artifici
thcell
site
measl
viru
commerci
licens
use
fmdv
peptid
vaccin
swine
requir
multipl
copi
peptid
present
investig
use
recombin
dna
technolog
fuse
small
peptid
sequenc
gene
code
larger
protein
order
produc
sever
novel
construct
use
peptid
sequenc
fuse
bacteri
protein
immunogen
potenti
advantag
complet
uniform
defin
structur
compar
uncharacter
variabl
natur
peptidecarri
conjug
prepar
chemic
crosslink
approach
use
express
fmdv
peptid
fuse
nterminu
bgalactosidas
e
coli
cell
bgalactosidas
chosen
shown
antibodi
produc
foreign
protein
locat
nterminu
known
contain
sever
helper
tcell
site
preliminari
experi
bgalactosidas
trple
fusion
protein
indic
multipl
copi
insert
peptid
sequenc
may
benefici
subsequ
immunogen
copi
fmdv
peptid
fuse
nterminu
bgalactosidas
studi
laboratori
anim
target
speci
protein
contain
one
copi
viral
determin
elicit
low
level
neutral
antibodi
wherea
protect
level
elicit
protein
contain
copi
determin
furthermor
singl
inocul
protein
contain
littl
mg
mg
peptid
respect
suffici
protect
laboratori
anim
challeng
infect
equival
mg
peptid
protein
also
protect
pig
challeng
infect
one
inocul
thu
immunogen
multipl
copi
peptid
bgalactosidas
fusion
protein
similar
obtain
use
synthet
multipl
antigen
peptid
system
develop
fusion
protein
concept
multipl
peptid
present
led
product
particul
structur
epitop
repeat
entir
surfac
similar
vlp
earliest
exampl
base
hbsag
hepat
b
core
antigen
hbcag
yeast
ty
protein
spontan
selfassembl
particl
respect
shown
use
hbcag
fusion
particl
cfp
immunogen
fmdv
peptid
approach
inactiv
viru
inde
littl
mg
fmdv
peptid
correspond
fusion
protein
present
surfac
cfp
gave
full
protect
guinea
pig
subsequ
experi
ntermin
cfp
shown
immunogen
free
disulfid
dimer
synthet
peptid
contain
band
tcell
determin
immunogen
carrierlink
peptid
activ
appear
depend
provis
tcell
help
hbcag
particl
format
cfp
also
immunogen
without
convent
vaccin
adjuv
wide
rang
speci
furthermor
system
respons
elicit
oral
nasal
administr
tcellindepend
manner
last
properti
cfp
offer
possibl
develop
vaccinebas
therapi
immunocompromis
individu
infect
immunodefici
virus
although
limit
number
peptidebas
vaccin
licens
date
offer
opportun
move
vaccin
rel
undefin
biolog
entiti
defin
pharmaceuticallik
product
use
elicit
immun
respons
wide
varieti
veterinari
virus
includ
rabi
viru
felv
bovin
rotaviru
bovin
enteroviru
canin
parvoviru
respiratori
syncyti
viru
equin
herp
viru
bovin
leukemia
viru
new
technolog
vaccin
also
use
valuabl
tool
diseas
control
erad
program
enabl
user
differenti
infect
vaccin
anim
marker
diva
differenti
infect
vaccin
anim
vaccin
recombin
delet
mutant
wildtyp
pathogen
subunitpeptid
vaccin
requir
accompani
diagnost
test
screen
make
possibl
vaccin
use
readili
nonendem
situat
earli
exampl
ration
attenu
glycoprotein
delet
mutant
use
control
pseudorabi
csf
pig
infecti
bovin
rhinotrach
cattl
live
attenu
vaccin
offer
sever
distinct
advantag
convent
inactiv
subunit
vaccin
replic
host
accur
franci
mimic
natur
infect
often
easi
administ
provid
longliv
immun
stimul
comprehens
immun
respons
includ
humor
antibodi
secretori
antibodi
cytotox
cell
reason
scientist
investig
way
deliv
subunit
peptid
vaccin
use
live
vector
viru
vector
viru
vector
studi
concentr
rel
larg
dna
virus
particular
poxvirus
herpesvirus
adenovirus
common
viru
vector
appli
experiment
orthopoxviru
vaccinia
success
use
vaccin
campaign
erad
smallpox
observ
segment
vaccinia
viru
genom
could
delet
without
affect
either
infect
abil
replic
led
develop
recombin
vaccinia
virus
insert
foreign
gene
inde
shown
base
pair
foreign
dna
insert
viru
offer
potenti
insert
sever
gene
singl
vector
produc
multicompon
vaccin
despit
numer
posit
observ
sever
potenti
problem
associ
use
vaccinia
produc
initi
recombin
possibl
cell
tropism
pathogen
may
affect
broad
host
rang
may
also
problem
viru
dissemin
recombin
poxvirus
field
condit
howev
biggest
question
undoubtedli
safeti
despit
excel
track
record
smallpox
erad
campaign
vaccinia
known
rare
occas
caus
seriou
advers
reaction
spite
reserv
vaccinia
recombin
use
strict
supervis
field
attempt
control
spread
rabi
wildlif
europ
north
america
view
promis
properti
much
attent
given
ration
attenu
vaccinia
viru
exampl
insert
tk
gene
shown
produc
mark
reduct
pathogen
delet
insert
investig
produc
safer
vector
gener
vaccin
purpos
one
vector
known
modifi
vaccinia
viru
ankora
recent
use
develop
vaccin
middl
east
respiratori
syndrom
coronaviru
infect
camel
altern
approach
activ
pursu
veterinari
purpos
use
poxvirus
restrict
host
rang
much
work
concentr
use
avipoxvirus
particular
fowlpox
canarypox
vector
variou
veterinari
speci
success
exploit
sever
diseas
includ
newcastl
diseas
avian
influenza
equin
influenza
rabi
felv
canin
distemp
poxvirus
studi
veterinari
vaccin
vector
includ
capripox
viru
rinderpest
racoonpox
rabi
parapox
pseudorabi
suipox
swine
influenza
myxomaviru
rabbit
hemorrhag
diseas
veterinari
herp
virus
eg
infecti
bovin
rhinotrach
viru
felin
herp
viru
pseudorabi
viru
adenovirus
eg
canin
equin
avian
chimpanze
adenoviru
also
develop
vector
one
particularli
notabl
exampl
herpesviru
turkey
particularli
success
appli
vector
within
poultri
industri
bival
vaccin
marek
diseas
ibr
ibd
ndv
addit
commerci
trival
vector
vaccin
recent
develop
marek
ndv
ibd
bacteri
vector
recent
studi
ration
attenu
bacteria
order
produc
suitabl
safe
oral
vaccin
introduc
possibl
use
vaccin
strain
gener
live
vector
foreign
protein
major
work
area
concentr
produc
invas
strain
salmonella
suffici
attenu
caus
pathogen
diseas
symptom
deliv
oral
host
initi
studi
look
gener
auxotroph
mutant
remov
modifi
import
gene
involv
aromat
aro
purin
pur
synthesi
pathway
auxotroph
attenu
reli
absenc
requir
nutrient
host
tissu
exampl
case
aro
mutant
critic
compound
probabl
paminobenzo
acid
doubl
aro
combin
aro
pur
mutant
gener
vaccin
result
somewhat
mix
howev
induct
local
system
antibodi
cellmedi
respons
follow
oral
immun
highlight
potenti
approach
success
attenu
vaccin
salmonella
poultri
produc
salmonella
also
use
experiment
vector
sever
antigen
includ
e
coli
shigella
dysenteria
helicobact
pylori
transmiss
gastroenter
viru
develop
field
come
studi
use
bacil
calmetteguerin
live
attenu
bovin
tubercl
bacillu
current
use
immun
human
tuberculosi
vector
mycobacterium
known
safe
immunogen
furthermor
given
singl
oral
dose
fairli
heat
stabl
inexpens
produc
result
engin
overexpress
homolog
well
heterolog
e
coli
enteroviru
protein
potenti
bacteri
vector
includ
vibrio
cholera
yersinia
enterocolitica
listeria
monocytogen
lactobacillu
casei
streptococcu
gordonii
protozo
vector
one
highli
novel
vector
technolog
base
use
live
protozoan
parasit
eimeria
genet
modifi
deliv
homolog
heterolog
antigen
poultri
vaccin
would
use
current
licens
commerci
attenu
strain
develop
vaccin
chicken
coccidiosi
foreign
gene
would
express
within
attenu
vector
use
enzymemedi
integr
result
transgen
strain
could
deliv
order
provid
broader
protect
coccidiosi
infect
dual
protect
coccidiosi
anoth
infecti
diseas
chicken
proof
concept
approach
recent
report
engin
modifi
strain
eimeria
tenella
deliv
cja
protein
campylobact
recombin
vaccin
shown
provid
immun
protect
campylobact
jejuni
challeng
compar
unvaccin
wildtyp
e
tenella
vaccin
control
p
rel
new
vaccin
technolog
fall
live
kill
approach
nucleic
acid
vaccin
vaccin
base
dna
clone
deliveri
plasmid
direct
inject
messeng
rna
produc
costeffect
endogen
protein
synthesi
mimic
natur
infect
thu
antigen
present
nativ
form
elicit
mhc
class
class
ii
tcell
respons
well
antibodi
respons
addit
risk
infect
vaccin
use
bypass
passiv
immun
first
licens
applic
technolog
control
infecti
hematopoiet
necrosi
viru
diseas
canadian
atlant
salmon
control
west
nile
viru
hors
dna
vaccin
also
licens
europ
salmon
pancrea
diseas
field
veterinari
vaccin
seen
mani
signific
advanc
technolog
past
year
introduct
sever
vaccin
base
novel
recombin
dna
technolog
vaccin
design
offer
farmer
owner
clinician
safer
efficaci
altern
exist
vaccin
technolog
addit
ad
advantag
eas
administr
improv
stabil
inde
mani
new
vaccin
technolog
often
find
first
commerci
applic
within
veterinari
medicin
current
interest
one
health
approach
human
anim
environ
veterinari
vaccin
import
role
play
develop
novel
approach
articl
cover
mani
new
inactivatedkil
attenuatedl
vaccin
strategi
avail
veterinari
research
worker
great
deal
still
need
understood
natur
respons
requir
elicit
full
protect
immun
sever
diseas
knowledg
enabl
develop
construct
new
gener
vaccin
defin
properti
alreadi
appar
veterinari
medicin
play
key
role
develop
clear
activ
research
area
offer
great
deal
potenti
develop
vaccin
technolog
futur
